Genetic Polymorphism oriented Phase II Study of Irinotecan and Doxifluridine for Unresectable or Recurrent Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: Irinotecan was infused 150 mg/m2 for pts with *1/*1 genotype and 70 mg/m2 for *1/*28. Irinotecan was infused 150 mg/m2 for pts with *1/*1 genotype and 70 mg/m2 for *1/*28. Primary outcome(s): Response rate Study Design: expanded access Non-randomized
创建时间：
2005-10-15
